ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.90
+1.01%Aug 24, 2026, 00:00 UTC
Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.
Aug 5, 2026, 20:00 UTC
Arcutis Biotherapeutics reported second quarter 2026 financial results with ZORYVE net product revenue of $129.9 million, up 59% year-over-year, and raised its full-year 2026 net product sales guidance to $525 million-$540 million.
Aug 5, 2026, 20:00 UTC
The FDA approved the expansion of ZORYVE cream 0.3% indication for topical treatment of plaque psoriasis in children down to age 2, marking Arcutis's seventh FDA approval in four years.
Source:Jul 8, 2026, 12:00 UTC
The FDA accepted Arcutis Biotherapeutics' supplemental New Drug Application for ZORYVE cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 to 24 months.
Jun 30, 2026, 13:15 UTC
Arcutis Biotherapeutics launched a new virtual health platform to expand access to its ZORYVE portfolio for chronic inflammatory skin diseases.
Jun 29, 2026, 23:06 UTC
The FDA approved Arcutis Biotherapeutics' ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2.
Source: